TABLE 2

Background regimen at baseline and during the 120 week study (efficacy (modified intent-to-treat) population)

Most frequently used anti-TB drugs in the background regimenBaseline
N=205
During the 120-week study
N=205
Fluoroquinolones#180 (87.8)185 (90.2)
 Ofloxacin101 (49.3)102 (49.8)
 Levofloxacin66 (32.2)79 (38.5)
Ethionamide or protionamide160 (78)175 (85.4)
Pyrazinamide152 (74.1)156 (76.1)
Aminoglycosides152 (74.1)154 (75.1)
Terizidone or cycloserine113 (55.1)130 (63.4)
Pas-c97 (47.3)123 (60)
Ethambutol109 (53.2)117 (57.1)
  • Data are presented as n (%). TB: tuberculosis. #: 20/205 (including seven with an extensively drug-resistant isolate) patients did not receive a fluoroquinolone during the 120-week study; gatifloxacin was received by one patient at baseline and one patient during the 120-week study; moxifloxacin was received by one and 29 patients, respectively; : excludes capreomycin.